Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Insights, Forecast to 2029

Publication ID:

PB504231852

Publication Date:

May 29, 2023

Pages:

106

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
麻豆原创 Analysis and Insights: Global Rheumatoid Arthritis (RA) Drugs 麻豆原创
The global Rheumatoid Arthritis (RA) Drugs market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Rheumatoid Arthritis (RA) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Rheumatoid Arthritis (RA) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Rheumatoid Arthritis (RA) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Rheumatoid Arthritis (RA) Drugs include AbbVie, Roche, Merck, HEYL Chemisch-pharmazeutische Fabrik, Johnson & Johnson, Amgen, Inc., Pfizer, Bristol-Myers Squibb and UCB, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Rheumatoid Arthritis (RA) Drugs market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Rheumatoid Arthritis (RA) Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Rheumatoid Arthritis (RA) Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Rheumatoid Arthritis (RA) Drugs revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Rheumatoid Arthritis (RA) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Rheumatoid Arthritis (RA) Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AbbVie, Roche, Merck, HEYL Chemisch-pharmazeutische Fabrik, Johnson & Johnson, Amgen, Inc., Pfizer, Bristol-Myers Squibb and UCB, etc.
By Company
AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Segment by Type
NSAIDs
Analgesic Drugs
Corticosteroids
DMARDs
Biological Therapies
JAK-inhibitors
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Rheumatoid Arthritis (RA) Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rheumatoid Arthritis (RA) Drugs companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rheumatoid Arthritis (RA) Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 NSAIDs
1.2.3 Analgesic Drugs
1.2.4 Corticosteroids
1.2.5 DMARDs
1.2.6 Biological Therapies
1.2.7 JAK-inhibitors
1.3 麻豆原创 by Application
1.3.1 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Perspective (2018-2029)
2.2 Global Rheumatoid Arthritis (RA) Drugs Growth Trends by Region
2.2.1 Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Rheumatoid Arthritis (RA) Drugs Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Rheumatoid Arthritis (RA) Drugs Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Rheumatoid Arthritis (RA) Drugs 麻豆原创 Dynamics
2.3.1 Rheumatoid Arthritis (RA) Drugs Industry Trends
2.3.2 Rheumatoid Arthritis (RA) Drugs 麻豆原创 Drivers
2.3.3 Rheumatoid Arthritis (RA) Drugs 麻豆原创 Challenges
2.3.4 Rheumatoid Arthritis (RA) Drugs 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Rheumatoid Arthritis (RA) Drugs by Players
3.1.1 Global Rheumatoid Arthritis (RA) Drugs Revenue by Players (2018-2023)
3.1.2 Global Rheumatoid Arthritis (RA) Drugs Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Rheumatoid Arthritis (RA) Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Concentration Ratio
3.4.1 Global Rheumatoid Arthritis (RA) Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rheumatoid Arthritis (RA) Drugs Revenue in 2022
3.5 Global Key Players of Rheumatoid Arthritis (RA) Drugs Head office and Area Served
3.6 Global Key Players of Rheumatoid Arthritis (RA) Drugs, Product and Application
3.7 Global Key Players of Rheumatoid Arthritis (RA) Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Type
4.1 Global Rheumatoid Arthritis (RA) Drugs Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted 麻豆原创 Size by Type (2024-2029)
5 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Application
5.1 Global Rheumatoid Arthritis (RA) Drugs Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2018-2029)
6.2 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type
6.2.1 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2018-2023)
6.2.2 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2024-2029)
6.2.3 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Type (2018-2029)
6.3 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application
6.3.1 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2018-2023)
6.3.2 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2024-2029)
6.3.3 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Application (2018-2029)
6.4 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country
6.4.1 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2018-2023)
6.4.3 North America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2018-2029)
7.2 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type
7.2.1 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Type (2018-2029)
7.3 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application
7.3.1 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Application (2018-2029)
7.4 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country
7.4.1 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2018-2029)
8.2 China Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type
8.2.1 China Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2018-2023)
8.2.2 China Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2024-2029)
8.2.3 China Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Type (2018-2029)
8.3 China Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application
8.3.1 China Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2018-2023)
8.3.2 China Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2024-2029)
8.3.3 China Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2018-2029)
9.2 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type
9.2.1 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Type (2018-2029)
9.3 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application
9.3.1 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Application (2018-2029)
9.4 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Region
9.4.1 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Rheumatoid Arthritis (RA) Drugs 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Rheumatoid Arthritis (RA) Drugs Introduction
11.1.4 AbbVie Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.1.5 AbbVie Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Rheumatoid Arthritis (RA) Drugs Introduction
11.2.4 Roche Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.2.5 Roche Recent Developments
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Rheumatoid Arthritis (RA) Drugs Introduction
11.3.4 Merck Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.3.5 Merck Recent Developments
11.4 HEYL Chemisch-pharmazeutische Fabrik
11.4.1 HEYL Chemisch-pharmazeutische Fabrik Company Details
11.4.2 HEYL Chemisch-pharmazeutische Fabrik Business Overview
11.4.3 HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Introduction
11.4.4 HEYL Chemisch-pharmazeutische Fabrik Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.4.5 HEYL Chemisch-pharmazeutische Fabrik Recent Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.5.5 Johnson & Johnson Recent Developments
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Details
11.6.2 Amgen, Inc. Business Overview
11.6.3 Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Introduction
11.6.4 Amgen, Inc. Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.6.5 Amgen, Inc. Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Rheumatoid Arthritis (RA) Drugs Introduction
11.7.4 Pfizer Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.7.5 Pfizer Recent Developments
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Details
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Introduction
11.8.4 Bristol-Myers Squibb Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.8.5 Bristol-Myers Squibb Recent Developments
11.9 UCB
11.9.1 UCB Company Details
11.9.2 UCB Business Overview
11.9.3 UCB Rheumatoid Arthritis (RA) Drugs Introduction
11.9.4 UCB Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.9.5 UCB Recent Developments
11.10 GSK
11.10.1 GSK Company Details
11.10.2 GSK Business Overview
11.10.3 GSK Rheumatoid Arthritis (RA) Drugs Introduction
11.10.4 GSK Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.10.5 GSK Recent Developments
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Rheumatoid Arthritis (RA) Drugs Introduction
11.11.4 Sanofi Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.11.5 Sanofi Recent Developments
11.12 Abbott Laboratories
11.12.1 Abbott Laboratories Company Details
11.12.2 Abbott Laboratories Business Overview
11.12.3 Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Introduction
11.12.4 Abbott Laboratories Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.12.5 Abbott Laboratories Recent Developments
11.13 Teva Pharmaceutical
11.13.1 Teva Pharmaceutical Company Details
11.13.2 Teva Pharmaceutical Business Overview
11.13.3 Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Introduction
11.13.4 Teva Pharmaceutical Revenue in Rheumatoid Arthritis (RA) Drugs Business (2018-2023)
11.13.5 Teva Pharmaceutical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.